NASDAQ LFVN opened at $15.09 on Tuesday. The firm’s 50-day moving average is $14.53 and its two-hundred day moving average is $12.74. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.67 and a quick ratio of 1.09. LifeVantage has a 12 month low of $10.62 and a 12 month high of $17.08. The stock has a market capitalization of $210.67 million, a P/E ratio of 25.58 and a beta of 0.64.
LifeVantage (NASDAQ:LFVN) last released its quarterly earnings results on Wednesday, October 30th. The company reported $0.13 EPS for the quarter, topping the consensus estimate of $0.12 by $0.01. LifeVantage had a return on equity of 38.13% and a net margin of 3.65%. The business had revenue of $56.23 million during the quarter. As a group, analysts anticipate that LifeVantage will post 0.67 EPS for the current year.
A number of hedge funds and other institutional investors have recently modified their holdings of LFVN. Acadian Asset Management LLC increased its position in shares of LifeVantage by 14.7% in the 2nd quarter. Acadian Asset Management LLC now owns 418,294 shares of the company’s stock valued at $5,430,000 after purchasing an additional 53,545 shares during the last quarter. Vanguard Group Inc. increased its holdings in LifeVantage by 4.8% in the second quarter. Vanguard Group Inc. now owns 665,728 shares of the company’s stock valued at $8,641,000 after buying an additional 30,342 shares during the last quarter. BlackRock Inc. increased its holdings in LifeVantage by 237.4% in the second quarter. BlackRock Inc. now owns 891,174 shares of the company’s stock valued at $11,568,000 after buying an additional 627,070 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its stake in LifeVantage by 21.6% in the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 46,104 shares of the company’s stock valued at $598,000 after buying an additional 8,175 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. raised its stake in LifeVantage by 214.7% in the second quarter. Jacobs Levy Equity Management Inc. now owns 117,545 shares of the company’s stock valued at $1,526,000 after buying an additional 80,199 shares in the last quarter. Institutional investors own 45.15% of the company’s stock.
LifeVantage Corporation engages in the identification, research, development, and distribution of nutraceutical dietary supplements and skin care products. The company offers Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skin care product; Axio, a line of energy drink mixes; Omega+, a fish oil dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and Vitamin D3; and PhysIQ, a weight management system, as well as Petandim for Dogs, a companion pet supplement formulated to treat oxidative stress in dogs.
Read More: Why do companies issue stock splits?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for LifeVantage Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeVantage and related companies with MarketBeat.com's FREE daily email newsletter.